LifeScan Inc.

Milpitas, CA, United States

LifeScan Inc.

Milpitas, CA, United States

Time filter

Source Type

— The research report titled “United States Blood Glucose Meter Market Insights, Opportunity, Analysis, Growth Potential & Forecast 2017 – 2022” examines the market, competitive landscape and trends of the United States Blood Glucose Meter Market. The study provides an in–depth analysis of the type 1, type 2 and newly diagnosed type 1 diabetes and overall diabetes population. Moreover, it also provides an essential insight on insulin users. Complete report on Blood Glucose Meter industry spread across 110 pages with providing 20 company Profiles, 20 tables and 14 figures is now available at http://www.marketreportsonline.com/587117.html Company Coverage of United States Blood Glucose Meter Market: Roche, LifeScan Inc, Abbott Diabetes Care, Arkray, Ascensia Diabetes Care, Fora Care, Entra Health, Fifty50 Medical, Infopia, Genesis Health Technologies, iHealth Labs, Oak Tree Health, Livongo Health, Nova Diabetes Care, Sanofi Diabetes, Telcare, Walgreens, U.S. Diagnostics, Prodigy Diabetes Care & Omnis Health Market growth can be attributed to factors such as increasing number of diabetic patients, growing awareness towards diabetes mellitus, improved glucose control and flexible, user–friendly design, government efforts for better management of diabetes mellitus and technological advancement in blood glucose meter devices. The report provides a decisive view on the Blood Glucose Meter Users and Market. It also covers reimbursement pattern and offers a clear view of the regulatory landscape in the United States Blood Glucose Meter Market. Key trends in terms of collaboration, partnership, distribution and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the United States Blood Glucose Meter Market. The report concludes with the profiles of major players in the United States Blood Glucose Meter Market. The key market players are evaluated on various parameters such as company overview, marketed products and latest development and trends of the Blood Glucose Meter Market. United States Diabetes Population (2011 – 2022) Insulin Users (2011 – 2022) United States Blood Glucose Meter Users and Market Analysis (2011 – 2022) United States Blood Glucose Meter Market: Reimbursement & Regulation System United States Blood Glucose Meter Market – Major Deal Types Key Companies Analysis Key Drivers and Inhibitors of the United States Blood Glucose Meter Market Order a copy of this “Global Blood Glucose Meter Market” research report at USD 990 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=587117 4. Key Drivers and Inhibitors of the United States Blood Glucose Meter Market 4.1 Market Drivers 4.2 Inhibitors Europe Blood Glucose Device (SMBG) (Test Strips, Lancet, Meter) Market & Forecast: The incidence of diabetes mellitus is on the rise throughout Europe and its showing no signs of slowing down in the near future. Approximately 60 Million Europeans are living with diabetes today, including more than 90% with type 2 diabetes and this trend is on rise. At present Europe Blood Glucose Monitoring Device Market is more than USD 7 Billion. Russia, United Kingdom and Italy are top three dominating countries in the European Blood Glucose Monitoring Devices market in 2015. Russia market share is expected to decline whereas United Kingdom share is likely to rise by 2020. Germany, Spain and Italy holds significant market share in Europe market place. Global Glucose Monitoring Market with Focus on CGM: Industry Analysis & Outlook (2016-2020): Glucose monitoring helps people suffering from diabetes in managing their health and avoiding its associated problems. Any individual can use the results of glucose monitoring to make decisions about food, physical activity, and medications which can help him stay healthy. The most common glucose monitoring solutions are blood glucose meters and continuous glucose monitoring (CGM) systems. In addition to it, the traditional way to check glucose levels involves pricking a fingertip with an automatic piercing device to obtain a blood sample and then using a glucose meter to measure the blood sample's glucose level. Explore More Related Reports on Medical Devices Market at http://www.marketreportsonline.com/cat/medical-devices-market-research.html For more information, please visit http://www.marketreportsonline.com/contacts/purchase.php?name=587117


News Article | May 2, 2017
Site: www.prnewswire.com

PENSACOLA, Fla., May 2, 2017 /PRNewswire/ -- Strategic Products Group, Inc., the only licensed dealer for the Unistrip diabetic test strip announce today that UniStrip Technologies, LLC and LifeScan have reached an agreement that clears the way for ALL diabetic test strip distributors and providers to offer UniStrip Generic Test Strips as the LOW-COST alternative to the higher priced OneTouch® Ultra test strips. This is a great news for all diabetic patients. UniStrip Generic Test Strips lower cost allows diabetic patients to test their blood glucose more frequently, giving them the opportunity to better manage their disease and live a healthier life.


Wiseguyreports.Com Adds “Blood Glucose Device (SMBG) (Test Strips, Lancet, Meter) -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database Blood glucose monitoring devices market is very lucrative business with enormous future potential. Self-monitoring blood glucose market is primarily dependent on number of diabetic patients. So with the growth in diabetic patients blood glucose monitoring devices market is set to grow many folds. By the end of 2013 there was 382 Million people suffering from diabetes and this figure is expect to rise further to 592 Million by 2035. For the year 2013 Self-monitoring blood glucose (SMBG) users has grown more than 50% from the number of users in 2007. China has the highest number of self-monitoring blood glucose device users but United States has highest number of test strips market share. Although self-monitoring blood glucose devices market is expected to grow with single digit CAGR, but its market is in double digit Billion US$. United States controls the highest market share in the self-monitoring blood glucose (SMBG) market worldwide. 4 companies Roche Diagnostic, LifeScan Inc., Bayer HealthCare and Abbott Laboratories together controls nearly 50% market share of self-monitoring blood glucose devices. Renub Research study titled “Blood Glucose Device (SMBG) (Test Strips, Lancet, Meter) Market & Forecast - Worldwide” analyzes the worldwide markets for, blood glucose test strips market, blood glucose lancet market and blood glucose meter market. This report studies separate comprehensive analytics for the 15 countries: United States, European Countries (United Kingdom, Germany, Spain, Italy, Netherlands, Norway, Sweden and Switzerland), BRIC countries (Brazil, Russia, India, China), Australia and Kuwait. Annual estimates and forecast are provided for the period of 2014 through 2020. A six year historic analysis is also provided for these markets. This 265 page report with 257 Figures and 12 Tables provides a complete analysis of top 15 countries of worldwide self-monitoring blood glucose (SMBG) market. All the 15 countries in the report have been studied from 7 viewpoints. • Countries Diabetes Population Scenario and Future Forecast • Countries Type 1 and Type 2 Diabetes Scenario and Future Forecast • Countries Self-Monitoring Blood Glucose (SMBG) devices Users and Future Forecast • Countries Self-Monitoring Blood Glucose devices (SMBG) Market and Future Forecast • Countries Blood Glucose Test Strips Market and Future Forecast • Countries Blood Glucose Lancet Market and Future Forecast • Countries Blood Glucose Meter and Future Forecast Leave a Query @ https://www.wiseguyreports.com/enquiry/529604-blood-glucose-device-smbg-test-strips-lancet-meter-market-forecast Top 15 Countries is Covered in this Report 4 Companies Revenue (Sales) from self-monitoring blood glucose (SMBG) devices have been analyzed in this report. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.


News Article | November 18, 2016
Site: marketersmedia.com

Blood Glucose Device (SMBG) (Test Strips, Lancet, Meter) -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021PUNE, INDIA - November 18, 2016 /MarketersMedia/ — Blood Glucose Device (SMBG) (Test Strips, Lancet, Meter) Industry Description Wiseguyreports.Com Adds “Blood Glucose Device (SMBG) (Test Strips, Lancet, Meter) -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database Blood glucose monitoring devices market is very lucrative business with enormous future potential. Self-monitoring blood glucose market is primarily dependent on number of diabetic patients. So with the growth in diabetic patients blood glucose monitoring devices market is set to grow many folds. By the end of 2013 there was 382 Million people suffering from diabetes and this figure is expect to rise further to 592 Million by 2035. For the year 2013 Self-monitoring blood glucose (SMBG) users has grown more than 50% from the number of users in 2007. China has the highest number of self-monitoring blood glucose device users but United States has highest number of test strips market share. Although self-monitoring blood glucose devices market is expected to grow with single digit CAGR, but its market is in double digit Billion US$. United States controls the highest market share in the self-monitoring blood glucose (SMBG) market worldwide. 4 companies Roche Diagnostic, LifeScan Inc., Bayer HealthCare and Abbott Laboratories together controls nearly 50% market share of self-monitoring blood glucose devices. Request for Sample Report @ https://www.wiseguyreports.com/sample-request/529604-blood-glucose-device-smbg-test-strips-lancet-meter-market-forecast Renub Research study titled “Blood Glucose Device (SMBG) (Test Strips, Lancet, Meter) Market & Forecast - Worldwide” analyzes the worldwide markets for, blood glucose test strips market, blood glucose lancet market and blood glucose meter market. This report studies separate comprehensive analytics for the 15 countries: United States, European Countries (United Kingdom, Germany, Spain, Italy, Netherlands, Norway, Sweden and Switzerland), BRIC countries (Brazil, Russia, India, China), Australia and Kuwait. Annual estimates and forecast are provided for the period of 2014 through 2020. A six year historic analysis is also provided for these markets. This 265 page report with 257 Figures and 12 Tables provides a complete analysis of top 15 countries of worldwide self-monitoring blood glucose (SMBG) market. All the 15 countries in the report have been studied from 7 viewpoints. • Countries Diabetes Population Scenario and Future Forecast • Countries Type 1 and Type 2 Diabetes Scenario and Future Forecast • Countries Self-Monitoring Blood Glucose (SMBG) devices Users and Future Forecast • Countries Self-Monitoring Blood Glucose devices (SMBG) Market and Future Forecast • Countries Blood Glucose Test Strips Market and Future Forecast • Countries Blood Glucose Lancet Market and Future Forecast • Countries Blood Glucose Meter and Future Forecast Leave a Query @ https://www.wiseguyreports.com/enquiry/529604-blood-glucose-device-smbg-test-strips-lancet-meter-market-forecast Top 15 Countries is Covered in this Report 1. United States 2. United Kingdom 3. Germany 4. Spain 5. Italy 6. Netherlands 7. Norway 8. Sweden 9. Switzerland 10. Brazil 11. Russia 12. India 13. China 14. Australia 15. Kuwait 4 Companies Revenue (Sales) from self-monitoring blood glucose (SMBG) devices have been analyzed in this report. • Roche Diagnostic • LifeScan Inc., • Bayer HealthCare • Abbott Laboratories Data Sources This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts. Primary sources include industry surveys and telephone interviews with industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases. Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=529604 Continued... Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK) For more information, please visit https://www.wiseguyreports.com/sample-request/529604-blood-glucose-device-smbg-test-strips-lancet-meter-market-forecastContact Info:Name: Norah TrentEmail: info@wiseguyreports.comOrganization: WISE GUY RESEARCH CONSULTANTS PVT LTDAddress: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, IndiaPhone: +91 841 198 5042Source: http://marketersmedia.com/global-blood-glucose-device-smbg-test-strips-lancet-meter-market-research-report-2016/144384Release ID: 144384


News Article | November 25, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Biosensors Market Size By Technology (Thermal, Electrochemical, Piezoelectric, Optical), By Application [Medical (Cholesterol, Blood Glucose, Blood Gas Analyzer, Pregnancy Testing, Drug Discovery, Infectious Diseases), Food Toxicity, Bioreactor, Agriculture, Environment], By End-User (Home Healthcare, PoC Testing, Food Industry, Research Labs, Security and Biodefense), Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, China, Japan, Mexico, Brazil, South Africa, Saudi Arabia), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2016  2024” new report to its research database. The report spread across 85 pages with table and figures in it. New discoveries in the field of medical science, government support, rising demand for point of care testing, and the global occurrence of chronic conditions like diabetes along with rapid & accurate detection of such conditions is anticipated to boost the demand for biosensors market over the coming years. The industry growth is expected to further receive a boost owing to the user-friendly as well as cost-effective nature of these biosensor devices. As per the reports of the international diabetes federation, the number of patients suffering from diabetes globally was 366 million in 2011 and the figure is predicted to touch 552 million by 2030.This enormous increase in the number of diabetic patients is expected to benefit the market over the coming years. As per Global Market Insights Inc. report, The biosensors market size worth USD 14.8 billion in 2015, is expected to surpass USD 29 billion by 2024, growing at a CAGR of 8% over the period of 2016-2024. Due to the interdisciplinary approach from various fields such as nanotechnology, medical science, and chemistry, biosensors have found large scale applications in various industries. The use of these biosensor devices in laboratories as well as self-testing coupled with beneficial government policies favoring expansion of genomics as well as proteomics is predicted to further complement the biosensors market growth over the coming years. Many of the IT giants such as Infosys, IBM, and TCS are making heavy investments in the industry and this is predicted to contribute significantly towards the revenue growth of the market over the coming years. Furthermore, growing patient awareness coupled with extended application of biosensors in medical, agriculture, food toxicity, environment, and bioreactor industries will boost the industry growth in near future.  U.S. Biosensors Market Size, By Application, 2012 - 2024 (USD Million) U.S. Biosensors Market Size, By Application, 2012 - 2024 (USD Million) Biosensors find major application in medical segment accounting for nearly 66% of the total revenue of the biosensors market. The largest revenue share can be credited to wide use of biosensors in medical sector. For instance, biosensors help in the diagnosis and monitoring of most of the chronic medical conditions such as cancer, diabetes, etc. Furthermore, the segment which was worth USD 9.8 billion in 2015, is predicted to witness a substantial surge over the coming eight years owing to innovations in optical quantum dots which are used in vaccine development, biopharmaceutical industry, and proteomic analysis. The blood glucose monitoring application held maximum share in medical segment and is projected to contribute over USD 15 billion in terms of revenue by 2024 due to rise in the global occurrence of diabetes. In addition to this, application of biosensors in agriculture segment is predicted to record a CAGR of 11% over the period of 2016-2024. Various technologies used in biosensors industry include optical biosensor, electrochemical biosensor, piezoelectric biosensor, and thermal biosensor technologies. The optical biosensor technology segment is predicted to grow rapidly at a rate of 8.7% over the period of 2016-2024. The electrochemical biosensor technology segment dominated the market by accounting nearly 71% of the overall revenue in 2015, and is expected to surpass USD 21 billion by 2024. This rapidly advancing biosensor technology makes better prediction of the metabolic state of the patient health. Biosensors finds its end-use applications in Biodefense, Home healthcare, Food industry, Point of Care testing, Security, and Research Labs. The end-use application of biosensors in point of care testing segment was worth USD 7 billion in 2015 and is predicted to witness a substantial growth over the coming eight years. Technological innovations leading to new products such as ultrasensitive printable biosensors are predicted to boost the segment growth. The biosensor application in the home healthcare segment is predicted to witness a CAGR of 8.5% over the period of 2016-2024. The Asia Pacific biosensors market is predicted to grow at a CAGR of 11.1% over the period of 2016-2024 due to rising awareness among the patients, growing healthcare access facility, and enhancing healthcare infrastructure. Japan, India, and China are predicted to contribute substantially towards the regional growth owing to rapid economic development and extensive R&D carried out in pharmaceuticals industry coupled with improved healthcare systems. The Latin America biosensors market is forecast to witness a significant surge over the period of 2016-2024. Mexico and Brazil are expected to be the major revenue pockets of the region. The North America market is projected to witness a substantial growth over the period of 2016-2024, owing to the growing occurrence of diabetes & heart diseases, favorable government policies, large number of clinical trials, and advanced healthcare infrastructure facility. The U.S. market is expected to contribute substantially towards the regional growth. Key industry participants include Abbott Laboratories, Johnson & Johnson, LifeScan Inc., Bayer Healthcare, EG &G IC Sensors, Ercon Inc., Biosensor International Ltd, Strategic Diagnostics Inc., and Sysmex Corporation. The market players will try to retain their market position by producing compact and effective biosensors over the coming timeframe. To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


Peyrot M.,Loyola University Maryland | Peyrot M.,Johns Hopkins University | Rubin R.R.,Johns Hopkins University | Chen X.,LifeScan Inc. | Frias J.P.,LifeScan Inc.
Diabetes Technology and Therapeutics | Year: 2011

Background: This study assessed the relationship between changes in glucose control and changes in patient-reported outcomes (PRO)-health-related quality of life (HR-QoL) and treatment satisfaction (TxSat)-in patients with type 2 diabetes initiating insulin pump therapy. Methods: Patients (n=54) initiating insulin pump therapy (Animas® 2020, Animas Corp., West Chester, PA) were studied for 16 weeks. Glucose control was measured with patient-blinded continuous glucose monitoring (CGM) (SEVEN™, DexCom, San Diego, CA) and unblinded glycosylated hemoglobin (A1C) and seven-point self-monitored blood glucose (SMBG) profiles. HR-QoL was measured using the Diabetes Symptom Checklist-Revised (DSC-R) and the EuroQol-5 Dimensions (EQ-5D). TxSat was measured using the Insulin Delivery System Rating Questionnaire (IDSRQ) clinical efficacy and treatment preference scales. Bivariate correlations assessed associations between measures of change from baseline. Results: Decreased A1C was associated only with improvement in IDSRQ clinical efficacy. For CGM and SMBG, reductions in mean glucose concentrations were associated with decreased DSC-R symptoms, improved EQ-5D health utility, and increased IDSRQ perceived clinical efficacy and treatment preference. Reduced glycemic variability was associated with improved EQ-5D health utility and increased IDSRQ treatment preference. CGM and SMBG readings from different times of day/night were differentially associated with all PRO. Conclusions: Findings suggest that A1C, representing an "average" of both high and low blood glucose values throughout the day, may not capture aspects of glucose control with the greatest impact on HR-QoL. Although TxSat was more strongly associated with A1C and mean glucose readings than with glycemic variability, HR-QoL was more strongly associated with glycemic variability. © Copyright 2011, Mary Ann Liebert, Inc.


Tunis S.L.,IMS Health | Willis W.D.,LifeScan Inc. | Foos V.,IMS Health
Current Medical Research and Opinion | Year: 2010

Objective: Stakeholders in Europe remain interested in assessments of country-specific value of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes treated with oral anti-diabetes drugs (OADs). This study used the IMS-CORE Diabetes Model to project the long-term (40-year) cost-effectiveness of SMBG at once, twice, or three times per day (vs. no SMBG) for this population from national reimbursement system perspectives in France, Germany, Italy, and Spain. Methods: SMBG input costs (strips, lancets, meters, nurse training) were supplied by LifeScan in E2007 values and applied as appropriate for each country's reimbursement policy. Cohort characteristics and assumed HbA1c effects came from a US Kaiser Permanente longitudinal analysis of new SMBG users. Country-specific estimations for use of screening programs and several concomitant medications, as well as mortality rates were used. Country-specific complication costs from published sources were inflated to E2007. Base case outcomes were discounted at 3% per annum for France, Germany, and Italy; 6% for Spain. Sensitivity analyses varied time horizon and discount rates for each country. They also included a 0.036 dis-utility for SMBG in year 1. Main outcome measures: Primary outcomes included total direct costs, gains in quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) over 40 years. Results: ICERs were largest in France (with meter costs included), and in Italy (with highest reimbursed costs for strips/lancets). ICERs for SMBG once, twice, and three times per day were E12 114, E6282, and E7958 (respectively) in France; and E12 694, E11 934, and E15 368 in Italy. ICERs for SMBG once or twice per day were5E2000 in Germany and5E4000 in Spain. ICERs for SMBG three times per day were5E6000/ QALY in both countries. Results were most sensitive to the 5-year time horizon, although ICERs for SMBG once per day were below E50 000/QALY in all countries but Italy (ICER = E77 064). Five-year ICERs for SMBG twice per day were below E40 000/QALY for all four countries, and those for SMBG three times per day were below E45 000/QALY. With the SMBG dis-utility, ICERs increased modestly (E321- E2264/ QALY) in all scenarios except SMBG once per day in France (E9578 increase) and Italy (E5979 increase). Study limitations include the use of relatively short-term data from a single US observational study for SMBG clinical effects, unknown levels of patient adherence, and assumptions regarding the duration of clinical effects. Conclusions: With cost assumptions reflecting current reimbursement levels in France, Germany, Italy, and Spain, SMBG was found to be cost-effective across a 40-year time horizon, with all base case ICERs 516 000/QALY. This study adds to the literature on the country-specific, long-term value of SMBG for type 2 diabetes patients treated with OADs. Under current model assumptions, variations in cost-effectiveness results stemmed primarily from payer reimbursement practices for SMBG within each country. © 2010 Informa UK Ltd.


Virdi N.S.,LifeScan Inc. | Mahoney J.J.,LifeScan Inc.
Journal of Diabetes Science and Technology | Year: 2012

Background: The clinical significance of blood glucose meter (BGM) error in the presence of increasing carbohydrate errors in diabetes patients who use both the BGM result and the carbohydrate estimation to dose insulin is unknown. Methods: This Monte Carlo simulation modeled diabetes patients who calculate insulin dosages based on BGM results and carbohydrate estimations. It evaluated the likelihood of on-target insulin dosing and clinically significant insulin dose errors based on data from five BGMs with diferent levels of performance (expressed as bias and imprecision [coeficient of variation (%CV)]) and increasing levels of carbohydrate estimation errors. The study was performed across three separate preprandial glucose (PPG) ranges (90-150, 150-270, and 270-450 mg/dl). Results: When carbohydrate estimation is accurate (%CV = 0%), the likelihood for on-target insulin doses ranged 50.1-98.5%. The likelihood depended on BGM performance and PPG range. In the presence of carbohydrate estimation errors (%CV = 5-20%), the likelihood of on-target insulin dosages markedly decreased (range, 27.2-80.1%) for all BGMs, the likelihood of insulin underdosing (range, 0-12.8%) and overdosing (range, 0-32.3%) increased, and the influence of BGM error on insulin dosing accuracy was blunted. Even in the presence of carbohydrate error, the BGM with the best performance (bias 1.35% and %CV = 4.84) had the highest probability for on-target insulin dosages. Conclusions: Both BGM and carbohydrate estimation error contribute to insulin dosing inaccuracies. The BGM with the best performance was associated with the most on-target insulin dosages. © Diabetes Technology Society.


Bergman E.,LifeScan Inc.
Journal of Diabetes Science and Technology | Year: 2012

This paper provides an introduction to "human factors engineering," an applied science that seeks to optimize usability and safety of systems. Human factors engineering pursues this goal by aligning system design with the perceptual, cognitive, and physical capabilities of users. Human factors issues loom large in the diabetes management domain because patients and health care professionals interact with a complex variety of systems, including medical device hardware and software, which are themselves embedded within larger systems of institutions, people, and processes. Usability considerations must be addressed in these systems and devices to ensure safe and efective diabetes management. © Diabetes Technology Society.


Katz L.B.,LifeScan Inc. | Dirani R.G.,LifeScan Inc. | Li G.,LifeScan Inc. | Randoll R.A.,LifeScan Inc. | Mahoney J.J.,LifeScan Inc.
Journal of Diabetes Science and Technology | Year: 2013

Background: Health care professionals (HCPs) routinely review handwritten blood glucose (BG) logbooks during office visits of patients with diabetes. Method: In this study, 64 HCPs were asked to assess glycemic patterns and estimate BG averages in six simulated handwritten logbooks. The HCPs then reviewed the pattern logs and averages in six OneTouch® Verio™IQ meters containing corresponding data sets. Results: The average time needed for pattern review was 7.3 min for handwritten logbooks versus 0.9 min using the meter. The total error rate for logbook pattern identification was 43.0% compared with the meter. The mean percentage deviation between HCP estimates of 30-day BG averages and actual values was 14.5%. Conclusions: The meter is associated with faster and more accurate pattern analysis compared with handwritten logbooks. © Diabetes Technology Society.

Loading LifeScan Inc. collaborators
Loading LifeScan Inc. collaborators